THC medication eliminates PTSD nightmares in over one-third of patients

For people living with post-traumatic stress disorder, the nights can be as brutal as the days. The brain, unable to fully process what it has witnessed, replays the trauma in vivid, involuntary detail—not as memory but as lived experience, night after night, until the person wakes gasping in panic. Existing medications offer little help. Antidepressants and blood pressure drugs might ease some symptoms of PTSD, but they rarely touch the nightmares themselves. In Germany, there isn't even a medication officially approved specifically for this purpose. That gap in treatment is what drew researchers at Charité—Universitätsmedizin Berlin to investigate whether a prescription form of THC, the primary psychoactive compound in cannabis, might do what conventional medicine could not.

The team, led by psychiatrist Stefan Röpke, suspected that THC might work where other drugs had failed because of how it interacts with the body's endocannabinoid system—the same system that regulates sleep, stress response, and the way emotional memories are processed and stored. During REM sleep, the phase when the brain consolidates experiences and manages emotions, THC appears to dampen dream activity itself, reducing the intensity of the nighttime reliving that torments people with PTSD. The theory was sound enough to test. In 2017, Germany had loosened restrictions on cannabis-based medicines, making clinical research more feasible. The researchers obtained Dronabinol, a prescription medication containing THC extracted directly from the cannabis plant and delivered as evening drops.

Over 170 people with severe, frequent PTSD nightmares enrolled in the study. For ten weeks, half received Dronabinol and half received a placebo that looked and tasted identical. Neither the participants nor the clinicians administering the treatment knew who was receiving what—the gold standard for testing whether a drug actually works or whether improvement comes from expectation alone. The results, published in Nature Medicine, were striking. On a scale measuring nightmare severity from zero to eight, the Dronabinol group saw their average burden drop by 3.7 points. The placebo group improved by 2.2 points. For people who had been waking in terror night after night, the difference was tangible.

More than one-third of those taking Dronabinol reported that their nightmares vanished entirely after the ten-week period. Another 21 percent said their nightmares had been cut at least in half. About five out of six people in the treatment group felt their overall health had improved markedly. The medication appeared to work specifically on the nightmare symptom and sleep quality rather than on PTSD as a whole—the researchers could not conclusively show it reduced the broader severity of post-traumatic stress or accompanying depression. But for people whose nights had become a second trauma, that specificity was enough. By interrupting the cycle of nocturnal reliving, the drug allowed them to sleep without dread.

The side effects were mild. Dizziness, headaches, and increased appetite occurred more often in the treatment group than in those taking placebo, but nothing severe emerged. Importantly, when participants stopped taking the medication at the end of the study, there were no withdrawal symptoms—no sign that the body had become dependent on the drug. That matters for a treatment meant to be used long-term. Still, questions remain. The study lasted only ten weeks. Researchers need to know whether Dronabinol remains safe and effective over months or years, and whether patients gradually build tolerance, requiring higher doses to achieve the same relief. The work involved multiple German research institutions and was supported by the pharmaceutical company Bionorica SE. What comes next is the harder part: determining whether this finding can become standard care for the thousands of people whose trauma lives in their sleep.